– USA, NC – Parexel, one of the world’s largest clinical research organizations providing the full range of Phase I to IV clinical development services, today announced the appointments of Michael Bruun and John Groetelaars to its Board of Directors, effective June 23, 2023.
“We are delighted to welcome Michael and John to the Parexel Board. Their deep knowledge and understanding of the global financial and healthcare landscape will be a great asset to the Board in guiding the next phase of Parexel’s growth,” said Board chair, Sheri McCoy.
About Michael Bruun
Michael Bruun joined Goldman Sachs in 2004 and is based in London. He holds a bachelor’s degree in economics from the University of Copenhagen and a master’s degree in economics from the University of Copenhagen, with studies at Cornell University. Mr. Bruun serves on the Boards of Directors at Advania, GS Wyvern, LRQA, Norgine, and Northvolt.
About John Groetelaars
John Groetelaars brings more than 30 years of global leadership experience acrossvariousf medical device sectors. Most recently, he was interim CEO for Dentsply Sirona (Nasdaq: XRAY), having previously served in a director role for the company. Before Dentsply Sirona, Mr. Groetelaars was President & CEO at Hillrom from May 2018 until the company’s acquisition by Baxter International, Inc. in 2021.
He earned his bachelor’s degree in Mechanical Engineering from Kettering University in Michigan and an MBA from Columbia University in New York.
About Parexel
Parexel is among the world’s largest clinical research organizations, providing the full range of Phase I to IV clinical development services to help life-saving treatments reach patients faster. Leveraging the breadth of our clinical, regulatory, and therapeutic expertise, our team of more than 21,000 global professionals works in partnership with biopharmaceutical leaders, emerging innovators, and sites to design and deliver clinical trials with patients in mind, increasing access and participation in making clinical research a care option for anyone, anywhere. Our depth of industry knowledge and strong track record gained over the past 40 years are moving the industry forward and advancing clinical research in healthcare’s most complex areas, while our innovation ecosystem offers the best solutions to make every phase of the clinical trial process more efficient. With people, insight, and focus on operational excellence, we work With Heart™ every day to treat patients with dignity and continuously learn from their experiences, so every trial makes a difference.
Source: https://www.parexel.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.